Risk prediction model of cardiotoxicity in breast cancer patients; the multicenter prospective CHECK HEART-BC (comprehensive heart imaging to evaluate cardiac damage linked with chemotherapy in breast

Abstract Background Cardiotoxicity due to cancer therapy has been emerging as an important issue along with the improvement in prognosis of breast cancer patients. Although the usefulness of global longitudinal strain and biomarker analysis was previously reported separately, there are few studies b...

Full description

Saved in:
Bibliographic Details
Published in:European heart journal 2023-11, Vol.44 (Supplement_2)
Main Authors: Terui, Y, Nochioka, K, Ota, H, Tada, H, Sato, H, Miyata, S, Toyoda, S, Shimojima, M, Izumiya, Y, Kitai, T, Yasuda, S, Sugimura, K
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background Cardiotoxicity due to cancer therapy has been emerging as an important issue along with the improvement in prognosis of breast cancer patients. Although the usefulness of global longitudinal strain and biomarker analysis was previously reported separately, there are few studies based on systematic evaluation of cardiotoxicity. Furthermore, large prospective cohort studies regarding cardiotoxicity and its prediction in breast cancer patients were also limited. Purpose Multicenter prospective study was performed to reveal the current characteristics of cardiotoxicity and develop a robust prediction model for cardiotoxicity using systematic evaluation of cardiac function. Methods and results Breast cancer patients who were scheduled for neoadjuvant and/or adjuvant chemotherapy were prospectively screened at the 25 participating institutions from August 2017 and March 2020. As a study protocol, follow-up visits were planned every 3 months from pre-treatment to 12 months after chemotherapy (median follow-up of 366 days). To evaluate their cardiac function, echocardiography, high-sensitive cardiac troponin, natriuretic peptide, and 12-lead ECG were acquired at every follow-up visit. cardiotoxicity was defined as a reduction in LVEF >10% point from baseline and to a value 64 bpm, LV end-systolic volume index >36.0 mL/m2, treatment with anthracycline, with radiation, with trastuzumab, and TAPSE
ISSN:0195-668X
1522-9645
DOI:10.1093/eurheartj/ehad655.2680